CoChat

Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease

Open access
Sela, Mor, Poley, Maria, Mora‐Raimundo, Patricia, Kagan, Shaked, Avital, Aviram, Kaduri, Maya, Chen, Gal, Adir, Omer, Rozencweig, Adi, Weiss, Yfat, Sade, Ofir, Leichtmann‐Bardoogo, Yael, Simchi, Lilach, Aga‐Mizrachi, Shlomit, Bell, Batia, Yeretz‐Peretz, Yoel, Or, Aviv Zaid, Choudhary, Ashwani, Rosh, Idan, Cordeiro, Diogo, Cohen‐Adiv, Stav, Berdichevsky, Yevgeny, Odeh, Anas, Shklover, Jeny, Shainsky‐Roitman, Janna, Schroeder, Joshua E., Hershkovitz, Dov, Hasson, Peleg, Ashkenazi, Avraham, Stern, Shani, Laviv, Tal, Ben‐Zvi, Ayal, Avital, Avi, Ashery, Uri, Maoz, Ben M., Schroeder, Avi · 2023 · Advanced Materials
Cited by 91

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although poor delivery to the brain hinders their therapeutic application. In the current study, it is demonstrated that brain‐targeted liposomes (BTL) enhance the delivery of mAbs across the blood‐brain‐barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of the PD brain. BTL are decorated with transferrin to improve brain targeting through overexpressed transferrin‐receptors on the BBB during PD. BTL are loaded with SynO4, a mAb that inhibits alpha‐synuclein (AS) aggregation, a pathological hallmark of PD. It is shown that 100‐nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to its target, thereby reducing AS aggregation, and enhancing neuronal viability. In vivo, intravenous BTL administration results in a sevenfold increase in mAbs in brain cells, decreasing AS aggregation and neuroinflammation. Treatment with BTL also improve behavioral motor function and learning ability in mice, with a favorable safety profile. Accordingly, targeted nanotechnologies offer a valuable platform for drug delivery to treat brain neurodegeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adma.202304654

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 64

  1. 10.1007/978-1-4613-0759-4_2 · DOI
  2. 10.1016/S1474-4422(07)70246-6 · DOI · Paper page
  3. 10.1016/j.nbd.2020.105028 · DOI · Paper page
  4. 10.1038/42166 · DOI · Paper page
  5. 10.1523/JNEUROSCI.4650-14.2015 · DOI · Paper page
  6. 10.4103/1673-5374.235013 · DOI · Paper page
  7. 10.3389/fnmol.2019.00299 · DOI · Paper page
  8. 10.1371/journal.pone.0019338 · DOI · Paper page
  9. 10.1523/JNEUROSCI.5314-13.2014 · DOI · Paper page
  10. 10.1016/j.nbd.2017.05.002 · DOI · Paper page
  11. 10.1021/acs.accounts.9b00277 · DOI · Paper page
  12. 10.1002/advs.202103240 · DOI
  13. 10.1002/advs.202301377 · DOI
  14. 10.1002/adhm.202100598 · DOI · Paper page
  15. 10.1007/s00262-006-0273-0 · DOI
  16. 10.3727/000000006783980946 · DOI · Paper page
  17. 10.1158/0008-5472.CAN-09-1157 · DOI · Paper page
  18. 10.1021/acsnano.9b01798 · DOI · Paper page
  19. 10.1038/s41563-023-01481-9 · DOI · Paper page
  20. 10.1021/acsnano.7b04495 · DOI · Paper page
  21. Betzer O., 2019, Proc. SPIE
  22. 10.7150/thno.41161 · DOI
  23. Lammers T., 2015, Adv. Funct. Mater., 2, 25
  24. 10.1038/s41467-023-37150-3 · DOI
  25. Attia S. A., 2021, Peptide Conjugation: Methods and Protocols
  26. 10.7150/thno.25228 · DOI · Paper page
  27. 10.1016/j.jconrel.2019.01.005 · DOI · Paper page
  28. 10.3389/fnins.2018.01019 · DOI · Paper page
  29. Gregoriadis G., 2010, Encyclopedia of Life Sciences
  30. 10.1073/pnas.1105786108 · DOI · Paper page
  31. 10.1021/nn305663e · DOI · Paper page
  32. 10.1126/sciadv.abj5435 · DOI
  33. 10.1002/advs.202101437 · DOI
  34. 10.1021/bc800233a · DOI · Paper page
  35. 10.1186/s12987-023-00450-3 · DOI
  36. 10.1006/dbio.2001.0439 · DOI · Paper page
  37. 10.1016/j.neuron.2019.11.028 · DOI
  38. 10.1021/mp800049w · DOI · Paper page
  39. 10.1111/j.1365-2990.1994.tb00997.x · DOI · Paper page
  40. 10.1007/s11095-022-03433-5 · DOI
  41. 10.1016/S0006-8993(96)01412-6 · DOI
  42. 10.1038/nrdp.2017.13 · DOI · Paper page
  43. 10.1186/s13024-020-00368-6 · DOI · Paper page
  44. 10.1016/j.redox.2021.101896 · DOI · Paper page
  45. 10.1038/s41531-022-00366-z · DOI
  46. 10.1016/S0166-2236(97)01139-9 · DOI · Paper page
  47. 10.1186/1756-6606-3-12 · DOI · Paper page
  48. 10.1016/j.nurt.2010.07.003 · DOI · Paper page
  49. 10.1007/s10637-017-0520-6 · DOI · Paper page
  50. 10.1038/nmeth.2019 · DOI · Paper page
  51. 10.1093/cercor/bht081 · DOI
  52. 10.1016/j.stemcr.2019.05.008 · DOI · Paper page
  53. 10.1063/5.0039366 · DOI
  54. 10.1038/nprot.2016.002 · DOI
  55. 10.1038/nmeth.1768 · DOI · Paper page
  56. 10.1016/j.neuron.2016.09.014 · DOI · Paper page
  57. 10.1093/bioinformatics/btu202 · DOI · Paper page
  58. 10.1038/nmeth.2089 · DOI · Paper page
  59. 10.7554/eLife.10032 · DOI · Paper page
  60. 10.1038/s41380-021-01281-0 · DOI
  61. 10.1073/pnas.1722677115 · DOI
  62. 10.1016/j.neuroscience.2013.08.021 · DOI
  63. 10.1016/j.expneurol.2008.03.007 · DOI
  64. 10.1016/j.brainresbull.2022.08.016 · DOI

Cited by

See all 91

Metadata

Authors
Sela, M., Poley, M., Mora‐Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., Sade, O., Leichtmann‐Bardoogo, Y., Simchi, L., Aga‐Mizrachi, S., Bell, B., Yeretz‐Peretz, Y., Or, A. Z., Choudhary, A., Rosh, I., Cordeiro, D., Cohen‐Adiv, S., Berdichevsky, Y., Odeh, A., Shklover, J., Shainsky‐Roitman, J., Schroeder, J. E., Hershkovitz, D., Hasson, P., Ashkenazi, A., Stern, S., Laviv, T., Ben‐Zvi, A., Avital, A., Ashery, U., Maoz, B. M., & Schroeder, A.
Venue
Advanced Materials
Publisher
Wiley
Published
2023-10-27
Volume
35
Issue
51
Pages
e2304654-e2304654
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W4387077144
Cited by
91
References
19
FWCI
5.01
Type
journal article
Language
en
Open access
hybrid
Funders
  • Israel National Institute for Health Policy Research (1R21AG074846‐01A1)
  • Michael J. Fox Foundation for Parkinson's Research (MJFF‐022407)
  • Teva Pharmaceutical Industries
  • Phospholipid Research Center (ASC‐2018‐062/1‐1)
  • Israel Science Foundation (2359/23, 2248/19, 1934/23, 2141/20, 1384/21, 1881/21)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease. https://app.cochat.ai/papers/10.1002/adma.202304654
The paper
Sela, M., Poley, M., Mora‐Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., Sade, O., Leichtmann‐Bardoogo, Y., Simchi, L., Aga‐Mizrachi, S., Bell, B., Yeretz‐Peretz, Y., Or, A. Z., Choudhary, A., Rosh, I., . . . Schroeder, A. (2023). Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease. Advanced Materials. https://doi.org/10.1002/adma.202304654

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.